Vita Coco Company, Inc. COCO 深 滬
等待開盤 04-01 09:30:00 美东时间
47.91
+1.390
+2.99%
華盛通- 最 高48.30
- 今 開47.52
- 成交量 133.15万股
- 最 低 45.02
- 昨 收 46.52
- 總市值 27.35亿
- 52周最高 61.39
- 市盈率 靜 40.28
- 換手率 2.33%
- 52周最低 29.74
- 委 比 -96.73%
- 總股本 5708.22万
- 歷史最高 61.39
- 量 比 0.44
- 振 幅 7.05%
- 歷史最低 7.39
- 每 手 1
- 風險率 9.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vita Coco shares are trading higher after the company announced it is set to join the S&P SmallCap 600 On March 25, 2026.
Vita Coco shares are trading higher after the company announced it is set to jo...
03-23 22:55
This Analyst Abandons Caution On Celsius After Powerful Q4
BofA upgrades Celsius (CELH) to Buy after a blowout Q4. Analyst Peter Galbo raises the price forecast to $65, citing strong 2026 momentum.
02-28 03:42
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
美股大行评级 | 潜在涨幅108.69%！Stephens & Co.维持圣玛丽石油勘测"超配"评级，上调目标价至49美元
今日重点评级关注：Stephens & Co.：维持圣玛丽石油勘测"超配"评级，目标价从48美元升至49美元；花旗：维持IDEAYA Biosciences"买入"评级，目标价从64美元升至65美元
02-20 15:57
Vita Coco shares are trading lower after the company reported worse-than-expected Q4 EPS results.
Vita Coco shares are trading lower after the company reported worse-than-expect...
02-19 01:53
财报速睇 | Vita Coco Company, Inc. 2025财年Q4营收1.28亿美元，同比增长0.4%；归母净利润0.06亿美元，同比增长64.0%
华盛资讯2月18日讯，Vita Coco Company, Inc.公布2025财年Q4业绩，公司Q4营收1.28亿美元，同比增长0.4%，归母净利润0.06亿美元，同比增长64.0%。
02-18 20:32
Insights into Vita Coco Q4 Earnings
The Q4 earnings report for Vita Coco (NASDAQ:COCO) was released on Wednesday, F...
02-18 20:02
Vita Coco Sees FY2026 Sales $680.000M-$700.000M vs $681.139M Est
Vita Coco (NASDAQ:COCO) sees FY2026 sales of $680.000 million-$700.000 million vs $681.139 million analyst estimate.
02-18 20:02
Earnings Scheduled For February 18, 2026
Companies Reporting Before The Bell • Global E Online (NASDAQ:GLBE) is projecte...
02-18 19:11
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
